135 related articles for article (PubMed ID: 2112055)
21. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study.
Bisagni G; Boni C; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A; Savoldi L
Tumori; 1998; 84(6):659-61. PubMed ID: 10080671
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide combination chemotherapy in advanced breast cancer.
Schmid H; Kaufmann M; Grischke EM; Bastert G
Cancer Chemother Pharmacol; 1990; 26 Suppl():S71-3. PubMed ID: 2347055
[TBL] [Abstract][Full Text] [Related]
23. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
Bellmunt J; Morales S; Navarro M; Solé LA
Cancer Chemother Pharmacol; 1990; 26 Suppl():S81-4. PubMed ID: 2347056
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
Willemse PH; vd Burg ME; vd Gaast A; Neijt JP; ten Bokkel Huinink WW; Aalders JG; de Vries EG
Cancer Chemother Pharmacol; 1990; 26 Suppl():S51-4. PubMed ID: 2112053
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer.
Focan C; Boossy J; Focan-Henrard D; Reginster M; Claessens JJ
Cancer Chemother Pharmacol; 1989; 23(3):192-3. PubMed ID: 2493996
[TBL] [Abstract][Full Text] [Related]
26. Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.
Cantwell BM; Harris AL; Bozzino JM
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S29. PubMed ID: 3028660
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Scheulen ME; Niederle N; Bremer K; Schütte J; Seeber S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
[TBL] [Abstract][Full Text] [Related]
28. High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
Güllü I; Yalçin S; Tekuzman G; Barişta I; Alkiş N; Celik I; Zengin N; Güler N; Kars A; Baltali E
Cancer Invest; 1996; 14(3):239-42. PubMed ID: 8630686
[TBL] [Abstract][Full Text] [Related]
29. Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
Toma S; Coialbu T; Biassoni L; Folco U; Gatti C; Canavese G; Giacchero A; Rosso R
Cancer Chemother Pharmacol; 1990; 26(6):453-6. PubMed ID: 2121378
[TBL] [Abstract][Full Text] [Related]
30. Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Wiltshaw E; Westbury G; Harmer C; McKinna A; Fisher C
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S10-2. PubMed ID: 3102088
[TBL] [Abstract][Full Text] [Related]
31. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
32. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
Langenbuch T; Mross K; Jonat W; Hossfeld DK
Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
[TBL] [Abstract][Full Text] [Related]
35. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
[TBL] [Abstract][Full Text] [Related]
39. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
Skubitz KM; Hamdan H; Thompson RC
Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
